SCHEMBL952341

SCHEMBL952341

CCC(=O)OC(=O)C(C)Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.37
TRPA1 O75762 1/20 0.37
NAAA Q02083 1/20 0.37
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
SOAT1 P35610 1/20 0.35
HIF1A Q16665 2/20 0.34
ESR1 P03372 1/20 0.34
CYP1A2 P05177 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
BLM P54132 1/20 0.33
WRN Q14191 1/20 0.33
ZDHHC7 Q9NXF8 1/20 0.32
FAAH O00519 1/20 0.32
ALOX15 P16050 1/20 0.32
MAPT P10636 1/20 0.31
LMNA P02545 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL28074303 0.91 FFAR3 (0.42) ALDH1A1TRPA1NAAAMGAMGAA
SCHEMBL28622651 0.88 ALDH1A1 (0.36) ALDH1A1TRPA1NAAA
SCHEMBL9305160 0.83 CYP2C19 (0.31) ALDH1A1TRPA1CYP2C19MAPT
SCHEMBL949443 0.83 TRPA1 (0.46) ALDH1A1TRPA1CYP2C19FAAH
SCHEMBL952339 0.81 SMN1; SMN2 (0.32) ALDH1A1SOAT1CYP2C19TSHR
SCHEMBL386957 0.79 NAAA (0.39) ALDH1A1TRPA1NAAAMGAMGAA
SCHEMBL288874 0.77 NAAA (0.38) ALDH1A1TRPA1NAAAMGAMGAA
SCHEMBL10829554 0.76 ALDH1A1 (0.42) ALDH1A1TRPA1NAAAMGAMGAA
SCHEMBL10700496 0.75 NAAA (0.37) ALDH1A1TRPA1NAAAMGAMGAA
SCHEMBL7707533 0.75 NAAA (0.37) ALDH1A1TRPA1NAAAMGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250235434-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE BioVersys AG (CH) 2025-07-24 US disclosed
EP-4508053-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE BioVersys AG (CH) 2025-02-19 EP disclosed
CN-118974060-A Rifabutin analogs for treating diseases 生物验证系统股份公司 2024-11-15 CN disclosed
WO-2023198597-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE BioVersys AG (CH) 2023-10-19 WO disclosed
US-20210388002-A1 DIMETHOXYBENZENE COMPOUND ANALOGS, METHODS FOR ANALYZING SAID COMPOUNDS AND STANDARD PRODUCTS OF SAID COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-12-16 US disclosed
US-20210387990-A1 METHOD FOR PRODUCING DIMETHOXYBENZENE COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-12-16 US disclosed
EP-3882248-A1 DIMETHOXYBENZENE COMPOUND ANALOGS, METHODS FOR ANALYZING SAID COMPOUNDS AND STANDARD PRODUCTS OF SAID COMPOUNDS Taiho Pharmaceutical Co., Ltd. (JP) 2021-09-22 EP disclosed
CN-113260618-A Dimethoxybenzene compound analogue, method for analyzing compound and standard substance of compound 大鹏药品工业株式会社 2021-08-13 CN disclosed
EP-3391100-B1 AMPHIPHILIC BRANCHED POLYDIORGANOSILOXANE MACROMERS ALCON INC (CH) 2020-08-12 EP disclosed
CN-111183148-A MIC-1 compounds and uses thereof 诺和诺德股份有限公司 2020-05-19 CN disclosed
US-10138316-B2 Amphiphilic branched polydiorganosiloxane macromers NOVARTIS AG (CH) 2018-11-27 US disclosed
EP-3391100-A1 AMPHIPHILIC BRANCHED POLYDIORGANOSILOXANE MACROMERS Novartis AG (CH) 2018-10-24 EP disclosed
US-9834642-B2 Method for sequentially synthesising poly(alkoxyamine amide)s, copolymers obtained and uses thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2017-12-05 US disclosed
WO-2017103792-A1 AMPHIPHILIC BRANCHED POLYDIORGANOSILOXANE MACROMERS NOVARTIS AG (CH) 2017-06-22 WO disclosed
US-20170166675-A1 AMPHIPHILIC BRANCHED POLYDIORGANOSILOXANE MACROMERS ALCON INC. (CH) 2017-06-15 US disclosed
US-20160222162-A1 METHOD FOR SEQUENTIALLY SYNTHESISING POLY(ALKOXYAMINE AMIDE)S, COPOLYMERS OBTAINED AND USES THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-08-04 US disclosed
US-20130030212-A1 COMPOUND HAVING ALICYCLIC STRUCTURE, (METH)ACRYLIC ACID ESTER, AND PROCESS FOR PRODUCTION OF THE (METH)ACRYLIC ACID ESTER IDEMITSU KOSAN CO., LTD. (JP) 2013-01-31 US disclosed
US-20130023693-A1 COMPOUND HAVING ALICYCLIC STRUCTURE, (METH)ACRYLIC ACID ESTER, AND PROCESS FOR PRODUCTION OF THE (METH)ACRYLIC ACID ESTER IDEMITSU KOSAN CO., LTD. (JP) 2013-01-24 US disclosed
US-20110009661-A1 COMPOUND HAVING ALICYCLIC STRUCTURE, (METH)ACRYLIC ACID ESTER, AND PROCESS FOR PRODUCTION OF THE (METH)ACRYLIC ACID ESTER IDEMITSU KOSAN CO., LTD. (JP) 2011-01-13 US disclosed
US-4192871-A ANAESTHETICS - STEROIDS GLAXO LABORATORIES LIMITED (GB) 1980-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130030212-A1 COMPOUND HAVING ALICYCLIC STRUCTURE, (METH)ACRYLIC ACID ESTER, AND PROCESS FOR PRODUCTION OF THE (METH)ACRYLIC ACID ESTER ALAD, MMAB, MAT1A ALDH1A1 313/4885TRPA1 3154/4885NAAA 469/4885
US-20130023693-A1 COMPOUND HAVING ALICYCLIC STRUCTURE, (METH)ACRYLIC ACID ESTER, AND PROCESS FOR PRODUCTION OF THE (METH)ACRYLIC ACID ESTER ALAD, MMAB, MAT1A ALDH1A1 313/4885TRPA1 3154/4885NAAA 469/4885
US-20250235434-A1 RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE RIF1, FNTB, Q6ZSR9 ALDH1A1 1724/4885TRPA1 4272/4885NAAA 2064/4885
US-20210387990-A1 METHOD FOR PRODUCING DIMETHOXYBENZENE COMPOUND CYP1B1, PAH, CYP4B1 ALDH1A1 40/4885TRPA1 748/4885NAAA 839/4885
US-20110009661-A1 COMPOUND HAVING ALICYCLIC STRUCTURE, (METH)ACRYLIC ACID ESTER, AND PROCESS FOR PRODUCTION OF THE (METH)ACRYLIC ACID ESTER ALAD, MMAB, MAT1A ALDH1A1 313/4885TRPA1 3154/4885NAAA 469/4885
US-20210388002-A1 DIMETHOXYBENZENE COMPOUND ANALOGS, METHODS FOR ANALYZING SAID COMPOUNDS AND STANDARD PRODUCTS OF SAID COMPOUNDS DDC, PAH, DDT ALDH1A1 12/4885TRPA1 623/4885NAAA 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.